4.7 Article

Contrasting pathogenesis of atopic dermatitis and psoriasis-Part II: Immune cell subsets and therapeutic concepts

期刊

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 127, 期 6, 页码 1420-1432

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2011.01.054

关键词

Atopic dermatitis; psoriasis; pathogenesis; therapy

资金

  1. Amgen
  2. Centocor
  3. Merck
  4. Eli Lilly

向作者/读者索取更多资源

Atopic dermatitis (AD) and psoriasis are among the most common inflammatory skin diseases. In the first part of this 2-part review, we discussed the similarities and differences between AD and psoriasis with respect to clinical features and pathology. The diseases are characterized by infiltration of skin lesions by large numbers of inflammatory cells; the second part of this review focuses on immune cell subsets that distinguish each disease and the therapeutic strategies that might be used or developed based on this information. We discuss the interactions among different populations of immune cells that ultimately create the complex inflammatory phenotype of AD and compare these with psoriasis. Therapeutic strategies have been developed for psoriasis based on the cytokine network that promotes inflammation in this disease. Antibodies against IL-12 and IL-23p40 antibody and antagonists of TNF are used to treat patients with psoriasis, and studies are underway to test specific antagonists of IL-23, IL-17, IL-17 receptor, IL-20, and IL-22. We discuss how these therapeutic approaches might be applied to AD. (J Allergy Clin Immunol 2011;127:1420-32.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据